Additionally, studies showed that in oxaliplatin (OXA)-resistant gastric cancer patients and those receiving neoadjuvant chemotherapy (NACT) with OXA plus S-1, LACTB expression is markedly downregulated, which is strongly correlated with poor treatment outcomes [40,41]. Here, LACTB is linked to gastric cancer.